Clinical trials: Sadness
Safety, Tolerability
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet
This is a Phase I clinical trial (protocol number: YR-011-B01) sponsored by Hangzhou Yirui Pharmaceutical Technology Co., Ltd., focusing on the novel oral small-molecule drug YR011 (active ingredient: PA032, a Kv1.3 channel…
- Conditions
- Safety, Tolerability, Pharmacokinetics
- Trial name
- NCT07285967
- Testing
- Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug)
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Social Anxiety Disorder
Computer-Based Treatment for Social Anxiety Disorder
The present study is an open trial that seeks to examine the feasibility, acceptability, mechanism, and efficacy of a recently developed computer-based therapy in individuals with social anxiety disorder (SAD)
- Trial name
- NCT03415022
- Testing
- computer-based treatment
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- New York State Psychiatric Institute
Healthy Volunteers
A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants
The purpose of this study is to evaluate the safety and pharmacokinetics of single-ascending doses of ZB004.
- Trial name
- NCT05794516
- Testing
- ZB004
- Where
- New Zealand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Zenas BioPharma (USA), LLC
Social Anxiety Disorder
Five Year Follow-up of Internet-based Cognitive Behaviour Therapy (CBT) for Social Anxiety Disorder (SAD)
Social anxiety disorder (SAD) is one of the most prevalent anxiety disorders in the western world. Cognitive behavioural therapy (CBT) is the psychological treatment that has the largest empirical support.
- Trial name
- SOFIE-5YFU (NCT01145690)
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- Karolinska Institutet
Social Anxiety Disorder (SAD)
A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder
This is a double-blind study to evaluate the efficacy and safety of ENX-102 in participants with social anxiety disorder (SAD).
- Trial name
- NCT07193563
- Testing
- ENX-102
- Where
- 20 sites in United States
- Volunteers
- 47 people
- Sponsor
- Engrail Therapeutics INC
Posttraumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD)
Metacognitive Therapy vs Unified Protocol for Patients With Comorbid Anxiety Disorders
The primary goal of this randomized controlled trial is to compare the effectiveness of two transdiagnostic psychological treatments, Metacognitive Therapy (MCT) and the Unified Protocol for Transdiagnostic Treatment of Emotional…
- Conditions
- Posttraumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Panic Disorder (With or Without Agoraphobia)
- Trial name
- NCT06971692
- Testing
- Metacognitive therapy (MCT), Unified protocol (UP)
- Where
- Sweden
- Volunteers
- 114 people
- Sponsor
- Karolinska Institutet
Advanced Solid Tumors
Phase 1 Trial of KH617
KH617 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Injection.
- Trial name
- NCT05667194
- Testing
- KH617
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sichuan Honghe Biotechnology Co., Ltd.
Septic Shock, Delirium
Septic Shock and Delirium Because of rSO2 Abnormalities in Intensive Care Unit Patients (The SAD BRAIN Study)
Delirium in the ICU is a prevalent problem occurring in up to 80% of ICU patients. A potential cause of delirium in ICU patients could be cerebral hypoxia. Septic shock is associated with high rates of delirium.
- Conditions
- Septic Shock, Delirium, Renal Failure
- Trial name
- NCT01836302
- Testing
- Observation
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- University of Manitoba
Asthma
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of AZD9898
In this integrated, multi-part, Phase I study, the safety, tolerability, food effect, pharmacokinetic (PK) and pharmacodynamic (PD) properties of single and repeated doses of AZD9898 will be investigated.
- Trial name
- NCT03140072
- Testing
- AZD9898
- Where
- 2 sites in United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Seasonal Affective Disorder
Optimizing Long-Term Outcomes for Winter Depression With CBT-SAD and Light Therapy
Major depression is a highly prevalent, chronic, and debilitating mental health problem with significant social cost that poses a tremendous economic burden.
- Trial name
- NCT03691792
- Testing
- Cognitive-Behavioral Therapy (CBT-SAD), Light Therapy
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- University of Vermont
Anxiety Disorders, Panic Disorder
Efficacy of Expectancy Focused Exposure Therapy for Anxiety Disorders
This clinical trial evaluates whether an optimized exposure-based treatment improves long-term outcomes for adults with anxiety disorders.
- Conditions
- Anxiety Disorders, Panic Disorder, Social Anxiety Disorder (SAD), Generalised Anxiety Disorder
- Trial name
- EFE-AD (NCT07753330)
- Testing
- Expectancy Focused Exposure, Anxiety Focused Exposure
- Where
- Chile
- Volunteers
- 203 people
- Sponsor
- University of Chile
Healthy, Osteoarthritis
Trichomylin® Safety, Tolerability & Pharmacokinetics in Healthy Adults and First in Human Osteoarthritis Pain Evaluation
This is a first in human, randomized, double-blind, placebo-controlled SAD (with food effect) followed by a MAD study of Trichomylin® conducted in healthy adult participants.
- Trial name
- HOPE (NCT04867057)
- Testing
- Trichomylin for SAD, Trichomylin for MAD
- Where
- Australia
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- ZYUS Life Sciences Inc.
Healthy Participants
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4144 administered orally in healthy participants.
- Trial name
- NCT06122714
- Testing
- AZD4144 Part A, AZD4144 Part B
- Where
- 2 sites in United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Airway Morbidity
Bronchoscopic Endotracheal Intubation Through a SAD - Physician Performance
Prospective observational study with the primary objective is to assess technical competence in anaesthesiology specialists who perform bronchoscopic endotracheal intubation through a supraglottic airway device (SAD), by using a…
- Trial name
- NCT04743440
- Testing
- Bronchoscopic endotracheal intubation through a supraglottic airway device
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Nordsjaellands Hospital
Cachexia
A Phase 1 Study of AV-380 in Healthy Subjects
This double-blinded, placebo-controlled, single ascending dose (SAD) study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity in healthy subjects of a single dose of AV-380.
- Trial name
- NCT04815551
- Testing
- AV-380
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- AVEO Pharmaceuticals, Inc.
Advanced Solid Tumor
Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours
This is the 'first-in-human' clinical trial of the Investigational Medicinal Product (IMP), Tablet formulation for Oral dosing of MSP008-22, a molecule (new chemical entity) with anticancer properties.
- Trial name
- NCT05478486
- Testing
- MSP008-22
- Where
- India
- Volunteers
- 7 people
- Sponsor
- Godavari Biorefineries Limited
Bacterial Infections
SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers
The worldwide spread of resistance to antibiotics among gram-negative bacteria, particularly members of the ESKAPE group of pathogens, has resulted in a crisis in the treatment of hospital acquired infections.
- Trial name
- QPX9003 (NCT04808414)
- Testing
- QPX9003 for IV Infusion
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.
Social Anxiety Disorder
Study of Vilazodone to Treat Social Anxiety Disorder
The purpose of this study is to determine whether Vilazodone is effective in the treatment of symptoms of Social Anxiety Disorder among adults.
- Trial name
- NCT01712321
- Testing
- Vilazodone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Medical Research Network
Healthy Volunteers
SAD and MAD Study of AKB-9090 in Healthy Adult Participants
This is a first-in-human (FIH study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic effects of AKB-9090 in healthy adult participants.
- Trial name
- NCT07429006
- Testing
- AKB-9090
- Where
- New Zealand
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Diabetes Mellitus, Type 2
A First-in-Human Study of LY3009385 in Healthy Participants
The main purpose of this study is to determine the safety of LY3009385 in healthy participants. The study drug is given as a single dose, by injections under the skin. Side effects will be documented.
- Trial name
- NCT01477567
- Testing
- LY3009385
- Where
- Singapore
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company